Christiana Friedman
Contributor since: 2017
Latest Articles
All Good News For Teva's Biosimilars As Sandoz Drops Out
New Data From Corbus For Lenabasum In Scleroderma Favors Approval Come 2020
The Future Doesn't Look Too Bright For Insys
The Big Question For GW Pharmaceuticals
Now Corbus Joins The NASH Fray
Looking For A Recession-Proof Stock? Look No Further Than Johnson & Johnson
Crispr Therapeutics Tries Its Hand At β-Thalassemia With Vertex
For Paratek, Only A Matter Of Time Before Stock Rises.Eventually
How The Diabetes Market May Soon Cross Over Into Parkinson's
Pfizer Is Not An All-Powerful Price-Hiker
AbbVie Trying Its Hand At All-In-One Screwdriver CAR-T Cancer Immunotherapy
Cellectis Is The Technological Leader Of CAR-T With CubiCAR, But Still Not A Buy
Translate Bio Could Be The Next Big Thing In Cystic Fibrosis
Novo's Oral Semaglutide Not Such A Clear Win Over Eli Lilly's Jardiance
For Esperion, The Only Trial That Matters Is CLEAR Outcomes Due In 2022
High Rates And Inflation Could Pose A Systemic Risk To Biotech
Ziopharm, Trump's Drug Pricing Plan And The Future Of Expensive Drug Development
2 Diabetes Growth Stocks And 1 Moonshot To Hold Through 2025
Pfizer's DMD Drug Could Spell Long-Term Trouble For Sarepta
Incyte's Failure With Merck's Keytruda Has No Implications For OncoSec
Cancer Vaccine With 97% Complete Response Rate In Mice Starts Human Trials
Novo Nordisk Can Succeed In Weight Loss Where Orexigen, Vivus, Arena Failed
3 Biotechs That Resisted The Recent Crash And Why
Teva Or Amgen/Novartis, Who Will Win The Battle For Migraine Market Share?
Hospital Stocks Could Rise This Year Because Of Inflation
3 Canadian Pot Stocks To Own In Preparation For Legalization
Epidiolex Approval Does Not Make GW Pharmaceuticals A Buy
Whether It Restructures Or Gets Acquired, Teva Is A Buy
Oramed: On To Phase III And The Tel Aviv Stock Exchange
3 New Developments Give Hope For Type I Diabetes Sufferers
Regeneron Will Still Be Heavily Reliant On Eylea Even If Sarilumab Becomes A Blockbuster
Novo Nordisk's New Hemophilia-B Drug Will Have A Hard Time Getting Through FDA Panel